GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » ROIC %

Scinopharm Taiwan (TPE:1789) ROIC % : 3.12% (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Scinopharm Taiwan's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2024 was 3.12%.

As of today (2025-03-24), Scinopharm Taiwan's WACC % is 4.26%. Scinopharm Taiwan's ROIC % is 3.70% (calculated using TTM income statement data). Scinopharm Taiwan earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Scinopharm Taiwan ROIC % Historical Data

The historical data trend for Scinopharm Taiwan's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan ROIC % Chart

Scinopharm Taiwan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.96 3.26 4.67 3.66 3.68

Scinopharm Taiwan Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.79 6.79 3.38 1.47 3.12

Competitive Comparison of Scinopharm Taiwan's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's ROIC % distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's ROIC % falls into.



Scinopharm Taiwan ROIC % Calculation

Scinopharm Taiwan's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROIC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=322.709 * ( 1 - 17.84% )/( (7204.144 + 7186.102)/ 2 )
=265.1377144/7195.123
=3.68 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11721.586 - 567.614 - ( 3949.828 - max(0, 729.453 - 6380.608+3949.828))
=7204.144

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11942.738 - 590.649 - ( 4165.987 - max(0, 767.682 - 6608.09+4165.987))
=7186.102

Scinopharm Taiwan's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2024 is calculated as:

ROIC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=264.832 * ( 1 - 14.46% )/( (7325.952 + 7186.102)/ 2 )
=226.5372928/7256.027
=3.12 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11784.304 - 480.687 - ( 3977.665 - max(0, 694.035 - 6487.102+3977.665))
=7325.952

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11942.738 - 590.649 - ( 4165.987 - max(0, 767.682 - 6608.09+4165.987))
=7186.102

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinopharm Taiwan  (TPE:1789) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Scinopharm Taiwan's WACC % is 4.26%. Scinopharm Taiwan's ROIC % is 3.70% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Scinopharm Taiwan ROIC % Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines